M
Maria Antonietta Di Rosolini
Publications - 7
Citations - 414
Maria Antonietta Di Rosolini is an academic researcher. The author has contributed to research in topics: Internal medicine & Hepatitis C. The author has an hindex of 2, co-authored 5 publications receiving 268 citations.
Papers
More filters
Journal ArticleDOI
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Vincenza Calvaruso,Giuseppe Cabibbo,Irene Cacciola,Salvatore Petta,Salvatore Madonia,Alessandro Bellia,Fabio Tinè,Marco Distefano,Anna Licata,Lydia Giannitrapani,Tullio Prestileo,Giovanni Mazzola,Maria Antonietta Di Rosolini,L. Larocca,Gaetano Bertino,A. Digiacomo,F. Benanti,Luigi Guarneri,A. Averna,Carmelo Iacobello,Antonio Magro,I. Scalisi,F. Cartabellotta,Francesca Savalli,Marco Barbara,Antonio Davì,Maurizio Russello,G. Scifo,Giovanni Squadrito,Calogero Cammà,Giovanni Raimondo,Antonio Craxì,Vito Di Marco,A. Craxì,V. Di Marco,C. Cammà,V. Calvaruso,Salvatore Petta,G. Cabbibbo,P. Colletti,G. Mazzola,Antonio Cascio,Giuseppe Montalto,A. Licata,L. Giannitrapani,T. Prestileo,F. Di Lorenzo,Adriana Sanfilippo,A. Ficalora,S. Madonia,F. Tinè,Giuseppe Malizia,Federica Latteri,Marcello Maida,F. Cartabellotta,R. Vassallo,I. Cacciola,Giuseppa Caccamo,S. Maimone,Carlo Saitta,G. Squadrito,G. Raimondo,Luigi Mondello,A. Smedile,S. D’Andrea,G. Bertino,A.L. Ardiri,E. Frazzetto,G. Rigano,Arturo Montineri,L.N. Larocca,Bruno Cacopardo,F. Benanti,M. Russello,R. Benigno,A. Bellia,C. Iacobello,A. Davì,M.A. Di Rosolini,A. Digiacomo,G. Fuduli,G. Scifo,M. Distefano,V. Portelli,F. Savalli,I. Scalici,G. Gioia,A. Magro,Giuseppe Alaimo,M.R. Alinovi,A. Salvo,A. Averna,F. Lomonaco,L. Guarneri,F. Maffeo,E. Falzone,F. Pulvirenti +96 more
TL;DR: In an analysis of data from a large prospective study of patients with hepatitis C virus-associated compensated or decompensated cirrhosis, it is found that the SVR to DAA treatment decreased the incidence of HCC over a mean follow-up of 14 months.
Journal ArticleDOI
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Giuseppe Cabibbo,Ciro Celsa,Vincenza Calvaruso,Salvatore Petta,Irene Cacciola,M.R. Cannavò,Salvatore Madonia,Margherita Rossi,Bianca Magro,Francesca Rini,Marco Distefano,L. Larocca,Tullio Prestileo,Giuseppe Malizia,Gaetano Bertino,F. Benanti,Anna Licata,I. Scalisi,Giovanni Mazzola,Maria Antonietta Di Rosolini,Giuseppe Alaimo,A. Averna,F. Cartabellotta,N. Alessi,Salvatore Guastella,Maurizio Russello,G. Scifo,Giovanni Squadrito,Giovanni Raimondo,Franco Trevisani,Antonio Craxì,Vito Di Marco,Calogero Cammà,Rete Sicilia Selezione Terapia – Hcv +33 more
TL;DR: In patients with HCV-related cirrhosis who had been successfully treated for early HCC, DAAs significantly improved OS compared with No DAA treatment, and sustained virologic response was a significant predictor of OS.
Journal ArticleDOI
Clinical characteristics and predictors of death among hospitalized patients infected with SARS-CoV-2 in Sicily, Italy: A retrospective observational study
Federica Cosentino,Vittoria Moscatt,Andrea Marino,Alessio Pampaloni,Daniele Scuderi,Manuela Ceccarelli,F. Benanti,M. Gussio,L. Larocca,V. Boscia,G Vinci,A. Zagami,A Onorante,Gaetano Lupo,Salvatore Torrisi,Silvana Grasso,Roberto Bruno,C. Iacobello,S. Bonfante,L. Guarneri,Antonio Cascio,A Franco,Rossella Del Vecchio,Maria Antonietta Di Rosolini,A. Pulvirenti,Damiano Larnè,Giuseppe Nunnari,Benedetto Maurizio Celesia,Bruno Cacopardo +28 more
TL;DR: Symptoms such as fatigue, older age, a number of co-pathologies and use of continuous positive airway pressure were the most significant contributors in the estimation of clinical prognosis.
Journal ArticleDOI
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort.
Vincenza Calvaruso,Salvatore Petta,Irene Cacciola,Giuseppe Cabibbo,F. Cartabellotta,Marco Distefano,G. Scifo,Maria Antonietta Di Rosolini,Maurizio Russello,Tullio Prestileo,Salvatore Madonia,Giuseppe Malizia,A. Montineri,A. Digiacomo,Anna Licata,F. Benanti,Gaetano Bertino,Marco Enea,Salvatore Battaglia,Giovanni Squadrito,Giovanni Raimondo,Calogero Cammà,Antonio Craxì,Vito Di Marco +23 more
TL;DR: Patients with SVR to a DAA therapy have a better liver and cardiovascular survival, and the effects of HCV eradication are most evident in patients with compensated liver disease.
Journal ArticleDOI
Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience
Luca Rinaldi,Vincenzo Messina,Vito Di Marco,Vincenzo Iovinella,Ernesto Claar,Giuseppe Cariti,Rodolfo Sacco,Massimo De Luca,G. Scifo,Pietro Gatti,Giorgio Barbarini,Valeria Pace Palitti,Mariano Quartini,Paolo Tundo,Gianpiero D'Offizi,Giustino Parruti,Maria Antonietta Di Rosolini,Giovanni Garrucciu,Lucio Cosco,F. Benanti,Giancarlo Gimignani,Umberto Vespasiani Gentilucci,Francesco Di Lorenzo,Maria D'Antò,Riccardo Nevola,Tommaso Lupia,Valerio Rosato,Valeria Morbiducci,Ilaria Luzzitelli,Federica Sozio,Marco Di Stefano,Emanuela Ciracì,Fabio Bulla,Riccardo Guarisco,Cecilia Cangiano,Michele Imparato,Paolo Maggi,Antonio Ascione,Antonio Craxì,Antonio Izzi +39 more
TL;DR: The performance of direct-acting antivirals in hepatitis C virus-infected people who use drugs (PWUDs) in terms of sustained virological response (SVR) and adherence rates in comparison to a location-matched cohort of non-PW UD HCV patients is excellent.